IVI RMA North America is the First and Only in Reproductive Medicine to Receive National Patient Safety Organization Designation

Newly established Institute for Safety in Reproduction will lead the work of RMA’s PSO and drive system-wide advances in safety, science, and quality outcomes

BASKING RIDGE, N.J.--(BUSINESS WIRE)--IVI RMA North America (IVI), a leader in fertility care and assisted reproduction, today announced the Institute for Safety in Reproductive Medicine (ISRM), a component Patient Safety Organization (PSO) of IVI, has been officially recognized by the Agency for Healthcare Research and Quality (AHRQ) and the U.S. Department of Health and Human Services (HHS) as the first and only PSO dedicated exclusively to the field of reproductive medicine. ISRM will drive system-wide advances in safety, science, and quality outcomes across fertility care.

“At IVI RMA, we bring dreams to life through cutting-edge innovation and individualized care—including leadership in patient safety,” said Lynn Mason, CEO of IVI RMA North America. "Becoming the first and only reproductive health organization with a component PSO focused exclusively on reproductive health is a milestone for our company and the entire field, and a reflection of our deep responsibility to the patients who place their trust in us. ISRM will help ensure that every advancement we make is grounded in safety, transparency, and the highest standard of care.”

Like all PSOs, ISRM will collect and analyze data on patient safety events within an environment designed to encourage transparency, learning and continuous improvement. The institute will serve as a collaborative space for clinicians across the network to share insights and identify changes that can improve safety in meaningful and measurable ways.

“Continuous learning is essential to delivering exceptional care and now, we’ll have powerful tools to turn our own data and the collective experiences of our clinical teams into actionable insights that can elevate care throughout IVI RMA,” said Thomas Molinaro, Chief Medical Officer of IVI RMA North America. “Establishing a component PSO is a very big step for IVI RMA. We are doubling down on creating a culture where safety is continuously measured, discussed, and elevated across every aspect of care.”

“This PSO fills a critical gap in reproductive medicine that gives our clinical team a space to openly learn from safety events and turn that learning into improvement,” said Hayley Rapp, DNP, RN, WHNP-BC, Compliance Medical & QA Director, IVI RMA North America. “In a field where science is always evolving, innovation means always finding new ways to advance care that is safe, thoughtful, and patient-centered.”

The PSO designation became effective on July 22, 2025. For more information about The Institute for Safety in Reproductive Medicine, visit https://pso.ahrq.gov/pso/institute-safety-reproductive-medicine-isrm.

About IVI RMA North America

IVI RMA North America, comprising Reproductive Medicine Associates, Boston IVF, and Toronto-based TRIO, spans 22 IVF laboratories and has helped women achieve pregnancies which have led to the birth of over 220,000 babies to date. Pioneers in innovative care, including PGT-A, single embryo transfer, fertility preservation, LGBTQ+ care, and more, the network has published over 1,000 papers which have pushed the fertility industry forward. Part of IVI RMA Global, one of the world's leading Reproductive Medicine groups committed to providing evidence-based fertility solutions with the greatest chance of success in the shortest time necessary to patients seeking treatment anywhere in the world. IVI RMA Global employs more than 4,500 people across 200+ locations in 15 countries. Learn more at rmanetwork.com and ivirma.com.